Intranasal drug delivery system- A glimpse to become maestro

Journal of Applied Pharmaceutical Science

Volumn 1, Issue 3, 2011, Pages 34-44

  Upadhyay, Shivam ^a   Parikh, Ankit ^a   Joshi, Pratik ^a   Upadhyay, U M ^b   Chotai, N P ^a  

^a A R Collage of Pharmacy ^*  (India)

^b Sigma Institute of Pharmacy   (India)

Author keywords

First pass elimination; Intranasal drug delivery; Mucociliary Clearance; Nasal cavity; Non Lipinski

Indexed keywords

EID: 84255181208     PISSN: None     EISSN: 22313354     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Alagusundaram M., Deepthi N., Ramkanth S., Angalaparameswari S., Mohamed Saleem T.S., Gnanaprakash K.. Thiruvengadarajan V. S, Madhusudhana Chetty C, Dry Powder Inhalers - An Overview, Int. J. Res. Pharm. Sci. 2010; 1(1): 34-42
2. Aemengot M., Basterra J and Macro J., Rev.Largol. Octol. Rhinol. 1990; 111, 219-226
3. Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discov Today 2002; 7,18, 967-975
4. Aulton M.E. "Pharmaceutics - The science of dosage form design" Churchill Livingston., 494, 2002, Krishnamoorthy R, Ashim K. Mitra, Prodrugs for nasal drug delivery. Advanced Drug Delivery Reviews1998; 29: 135-146
5. Aurora J. Development of Nasal Delivery Systems: A Review. Drug Deliv Technol 2002; 2, 7, 1-8.
6. Aurora J. Development of Nasal Delivery Systems: A Review. Drug Deliv Technol 2002; 2, 7, 1-8.
7. Bawarshi RN, Hussain A, Crooks PA. Nasal absorption of 17aethinyloestradiol in the rat. J Pharm Pharmacol 1989; 41: 214-215.
8. Bernstein J.M., Reddy M.S.,. Scannapieco F.A, Faden H.S., Ballow M., The microbial ecology and immunol- ogy of the adenoid: implications for otitis media, Ann. N.Y. Acad. Sci. 1997, 830, 19-31.
9. Ramesh R.P., Mahe et al. Bioavailability of Intranasal Drug Delivery System, Asian Journal of Pharmaceutics - October-December 2008, 201-215
10. Bloebaum, R.M., 2002. Managing allergic rhinitis: The role of pharmacotherapy; sound treatment can improve your patients quality of life. J. Respir. Dis. 23, 370376
11. Boston: Academic Press. ISBN 0-12-256971-7,2001
12. Chien Y.W., Su K.S.E., Chang S.F., Nasal Systemic Drug Delivery, Ch. 1, Marcel-Dekker, New York, 1-77, 1989
13. Chien YW, Chang SF. Intranasal drug delivery for systemic medications. Crit Rev Ther Drug Carr Syst 1987; 4: 67-194
14. Chien YW, Chang SF. Intranasal drug delivery for systemic medications. Crit Rev Ther Drug Carr Syst 1987; 4: 67-194
15. Corbo DC, Liu JC, Chien YW. Characterization of the barrier properties of mucosal membranes. J Pharm Sci 1990; 79: 202-206.
16. Costantino, H.R., Sileno, A.P., Johnson, P.H., 2005. Pharmacokinetic attributes of intranasal delivery: case studies and new opportunities. ON Drug Delivery 3, 811
17. Donnelly A, Kellaway IW, Taylor G, Gibson M. Absorption enhancers as tools to determine the route of nasal absorption of peptides. J Drug Target 1998; 5: 121-127
18. Edman P, Bjork E, Ryden L. Microspheres as a nasal delivery system for peptidedrugs j controlled release, 1992; 21: 165-172
19. Finlay, Warren H. The mechanics of inhaled pharmaceutical aerosols: an introduction. Boston: Academic Press. ISBN 0-12-256971-7, 2001.
20. Finlay, Warren H. The mechanics of inhaled pharmaceutical aerosols: an introduction.
21. Franz, M.R., Oth, M.P., U.S patent, 5232704, 1993
22. Gizurarson S, Bechgaard E. Intranasal administration of insulin to humans. Diabetes Res Clin Prac 1991; 12: 71-84
23. H.R. Costantino et al. Intranasal delivery: Physicochemical and therapeutic aspects International Journal of Pharmaceutics 337 (2007) 1-24
24. Harris AS, Nilsson IM, Wagner ZG, Alkner U. Intranasal admini- stration of peptides: nasal deposition, biological response, and absorption of desmopressin. J Pharm Sci 1986; 75(11): 1085-1088
25. Hirai, S., Yashiki, T., Mima, H., Effect of surfactants on nasal absorption of insulin in rats, Int. J. Pharm., 1981,9, 165-171.;
26. Hofstee BH. Specificity of esterase. II. Behavior of pancreatic esterase I and II toward a homologous series of N-fatty acid esters. J Biol Chem, 1952; 199: 365-371
27. Hughes B.L., Allen D.L., Dorato M.A., Wolff R.K., Effect of devices on nasal deposition and mucociliary clearance in rhesus monkeys, Aerosol Sci. Technol. 1993,18, 241-249.
28. Hughes B.L., Allen D.L., Dorato M.A., Wolff R.K., Effect of devices on nasal deposition and mucociliary clearance in rhesus monkeys, Aerosol Sci. Technol. 1993,18, 241-249
29. Hussain A, Hamadi S, Kagoshima M, Iseki K, Dittert L. Does increasing the lipophilicity of peptides enhance their nasal absorption. J Pharm Sci 1991; 80: 1180-1181.
30. Hussain AA, Foster T, Hirai S, Kashihara T, Batenhorst R, Jone M. Nasal absorption of propranolol in humans. J Pharm Sci 1980; 69: 1240-1243.;
31. Hussain MA, Koval CA, Shenvi AB, Aungst BJ, Recovery of rat nasal mucosa from the effects of aminopeptidase inhibitors. J Pharm Sci 1990; 79: 398-400
32. Hussain MA, Koval CA, Shenvi AB, Aungst BJ, Recovery of rat nasal mucosa from the effects of aminopeptidase inhibitors. J Pharm Sci 1990; 79: 398-400
33. Illum L. In: Mathiowitz E, Chickering DE, Lehr CM Ed, Bioadhesive formulations for nasal peptide delivery: Fundamentals, Novel Approaches and Development. Marcel Dekker. New York; 507-539, 1999;
34. Illum, L., 2004. Is nose-to-brain transport of drugs in man a reality? J. Pharm. Pharmacol. 56, 317;
35. Inagaki M, Sakakura Y, Itoh H, Ukai K, Miyoshi Y. Macromolecular permeability of the tight junction of human nasal mucosa. Rhinology, 1985; 23: 213-221.
36. Janssens, M.M., Vanden-Bussche, G., 1991. Levocabastine: an effective topical treatment of allergic rhinoconjunctivitis. Clin. Exp. Allergy 21, 2936
37. Johnson, P.H., Quay, S.C., 2005. Advances in nasal drug delivery through tight junction technology. Expert Opin. Drug Deliv. 2, 281-298.
38. Junginger HE. Mucoadhesive hydrogels. Pharmazeutische Industrie 1956; 53: 1056-1065.
39. Kadam, S.S., Mahadik, K.R., Pawar, A.P., Paradkar, A.R., Transnasal delivery of peptides - a review, The East. Pharm. July 1993, 47-49.
40. Kaliner M., Marom Z., Patow C., Shelhamer J, Human respiratory mucus, J. Allergy Clin. Immunol. 1984, 73, 318-323.
41. Kemble, G., Greenberg, H., 2003. Novel generations of influenza vaccines. Vaccine 21, 1789-1795
42. Kisan R. Jadhav,Manoj N. Gambhire, Ishaque M. Shaikh, Vilarsrao J. Kadam and Sambjahi S. Pisal, Nasal Drug Delivery System-Factors Affecting and Applications, Current Drug Therapy, 2007, 2, 27-38 27
43. Knoch, M. & Finlay, W. H. "Nebulizer Technologies",Chapter 71 in Modified-Release Drug Delivery Technology, ed. Rathbone/Hadgraft/Roberts, MarcelDekker, pp. 849-856, 2002
44. Krishnamoorthy R, Ashim K. Mitra, Prodrugs for nasal drug delivery. Advanced Drug Delivery Reviews 1998; 29: 135-146, 1998;
45. L. Illum, Improved delivery of drugs to mucosal services, European patent EP0975367B1, 2000.
46. L. Illum, Improved delivery of drugs to mucosal services, European patent EP0975367B1, 2000.
47. L. Illum, Is nose-to-brain transport of drugs in man a reality? J. Pharm. Pharmacol. 56 (2004) 3-17.
48. L. Illum, Is nose-to-brain transport of drugs in man a reality? J. Pharm. Pharmacol. 56 (2004) 3-17.
49. L. Illum, Nasal drug delivery - possibilities, problems and solutions, J. Control. Release 87 (2003) 187-198.
50. L. Illum, Nasal drug delivery-possibilities, problems and solutions Journal of Controlled Release 87 (2003) 187-198
51. L. Illum, Nasal drug delivery-possibilities, problems and solutions Journal of Controlled Release 87 (2003) 187-198
52. Lee, V.H., 1988. Enzymatic barriers to peptide and protein absorption. Crit. Rev. Ther. Drug Carrier Syst. 5, 69-97.
53. Lee, V.H., 1988. Enzymatic barriers to peptide and protein absorption. Crit. Rev. Ther. Drug Carrier Syst. 5, 69-97.
54. Liu X, Fawcett JR, Thorne RG, Frey WH (2001b) Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusion. Neurosci Lett 308:91-94.
55. M.Alagusundara et al, Nasal drug delivery system - an overview Int. J. Res. Pharm. Sci. Vol-1, Issue-4, 454-465, 2010
56. Mahalaxmi rathananand, D. S. Kumar, A. Shirwaikar, Ravi kumar, D. Sampath kumar, Preparation of Mu-coadhesive Microspheres for Nasal Delivery by Spray Drying, Indian Journal of Pharmaceutical Sciences, 2007, 652.
57. Martin E, Nicolaas GM, Schipper J, Coos V,Frans WH. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Del Rev 1997; 29: 13-38
58. Michael I. Ugwoke, Remigius U. Agu, Norbert Verbeke, Renaat Kinget, Nasal mucoadhesive drug delivery: Background, applications, trends and future perspec- tives, Advanced Drug Delivery Reviews, 2005, 57, 1640-1665
59. Milford, C.A., Mugliston, T.A., Lund, V.J., Mackay, I.S., 1990. Long-term safety and efficacy study of intranasal ipratropium bromide. J. Laryngol. Otol. 104, 123-125
60. Mygind N., Vesterhauge S., Aerosol distribution in the nose, Rhinology 1978,16, 79-88.
61. Newhouse M.T., Advantages of pressured canister metered dose inhalers, J. Aerosol Med. 1991,4, 139- 150.
62. Ohwaki K, Ando H, Watanabe S, Miyake Y, Effects of dose, pH and osmolarity on nasal absorption of secretin in rats, J Pharm Sci 1985; 74: 550-552
63. R. G. Thorne et al, delivery of insulin-like growth factor-i to the rat brain And spinal cord along olfactory and trigeminal pathways following intranasal administration neuroscience 127 (2004) 481-496
64. R.G. Thorne, G.J. Pronk, V. Padmanabhan, W.H. Frey II, Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration, Neuroscience 127 (2004) 481-496.
65. R.J. Soane, M. Frier, A.C. Perkins, N.S. Jones, S.S. Davis, L. Illum, Evaluation of clearance characteristics of bioadhesive systems in humans, Int. J. Pharm. 78 (1999) 55-65.
66. Ramesh RP, Mahesh C, Patil, O. Obire. Nasal Drug delivery in Pharmaceutical and biotechnology: present and future, e-Journal of Science & Technology, 2009; 3 : 1-21
67. Remeo VD et al., 1998
68. Roth, Y., Chapnik, J.S., Cole, P., 2003. Feasibility of aerosol vaccination in humans. Ann. Otol. Rhinol. Laryngol. 112, 264270
69. Sarkar M.A., Drug metabolism in the nasal mucosa, Pharm.Res. 1992, 9, 1-9.
70. Soane RJ, Hinchcliffe M , Davis SS, Illum L. Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int J Pharm 2001; 217: 183-191
71. Stanaland, B.E., 2004. Once-daily budesonide aqueous nasal spray for allergic rhinitis: a review. Clin. Ther. 26, 473492
72. Striebel H.W., Kramer J., Luhman I., Rohierse-Hohler I., Rieger A. Pharmakokinetic he studie zur intranasal engabev on fentanyl, Der Schmerz.1993, 7,122-125.
73. Van Drunen, C., Meltzer, E.O., Bachert, C., Bousquet, J., Fokkens, W.J., 2005. Nasal allergies and beyond: a clinical review of the pharmacology, efficacy, and safety of mometasone furoate. Allergy 60, 519
74. Vyas, T.K., Shahiwala, A., Marathe, S., Misra, A., 2005. Intranasal drug delivery for brain targeting. Curr. Drug Deliv. 2, 165175
75. Wolfe, T., Barton, E., 2003. Nasal drug delivery in EMS: reducing needlestick risk. JEMS 28, 5263
76. Zia H., Dondeti P., Needham T.E., Intranasal drug delivery, Clin. Res. Reg. Affairs , 1993, 10, 99-135
77. Zuercher, A.W., Coffin, S.E., Thurnheer, M.C., Fundova, P., Cebra, J.J., 2002. Nasal-associated lymphoid tissue is a mucosal inductive site for virus-specific humoral and cellular immune responses. J. Immunol. 168, 17961803